StockNews.AI
EYPT
StockNews.AI
174 days

EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025

1. EYPT to report Q4 and full-year 2024 results on March 5, 2025. 2. DURAVYU™ is in Phase 3 trials for wet AMD, a major vision loss cause. 3. Positive Phase 2 trial results may lead to pivotal program discussions in 2025. 4. EYPT's pipeline includes innovative treatments for retinal diseases using Durasert E™ technology. 5. DURAVYU™ has not yet received FDA approval; timelines remain uncertain.

Earnings
+6.38%Current Return
VS
+0.03%S&P 500
$5.9602/26 07:06 AM EDTEvent Start
$6.3402/27 01:44 PM EDTLatest Updated
5m saved
Insight
Article

FAQ

Why Bullish?

The upcoming financial results and promising clinical data can boost investor confidence, similar trends were observed with other biopharma companies announcing positive trial results.

How important is it?

The article's insights on DURAVYU™ and upcoming earnings could significantly impact EYPT's stock price, reflecting the company's potential and current positioning in the market.

Why Short Term?

Investor sentiment is likely to react immediately following the Q4 results and updates surrounding the Phase 3 trials.

Related Companies

RGCREGNNVCR
WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 5, 2025 to report its fourth quarter and full-year 2024 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio conference link: https://register.vevent.com/register/BI804e9c71d61543cab2c16376caae4936. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointpharma.com. A webcast replay will also be available on the corporate website at the conclusion of the call. About EyePoint EyePoint (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery. The Company’s lead product candidate, DURAVYU™ is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E™. Supported by robust safety and efficacy data to date, DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD), the leading cause of vision loss among people 50 years of age and older in the United States, and recently completed a Phase 2 clinical trial in diabetic macular edema (DME). Based on positive Phase 2 results from the VERONA clinical trial in DME, EyePoint anticipates meeting with U.S. and ex-U.S. regulatory agencies in the second quarter of 2025 to confirm plans for a pivotal program. Pipeline programs include EYP-2301, a TIE-2 agonist, razuprotafib, formulated in Durasert E™ to potentially improve outcomes in serious retinal diseases. The proven Durasert® drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products in multiple disease indications. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan. DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain. Investors: Christina TartagliaPrecision AQDirect: 212-698-8700christina.tartaglia@precisionaq.com Media Contact: Amy PhillipsGreen Room CommunicationsDirect: 412-327-9499aphillips@greenroompr.com

Related News